Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: A 3-year follow-up

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1481-1489

  Rallidis, Loukianos S ^a   Kotakos, Christos ^a   Sourides, Vassilios ^a   Varounis, Christos ^a   Charalampopoulos, Athanasios ^b   Zolindaki, Maria ^b   Dagres, Nikolaos ^a   Papadopoulos, Costas ^a   Anastasiou Nana, Maria ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

Author keywords

LDL cholesterol target; stable coronary heart disease; statins; very high risk patients

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONCENTRATION (PARAMETERS); CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DEPRESSION; DIABETES MELLITUS; DIET RESTRICTION; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDITERRANEAN DIET; METABOLIC DISORDER; MONOTHERAPY; OBESITY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL ACTIVITY; PREDICTOR VARIABLE; PROGNOSIS; REVASCULARIZATION; RISK ASSESSMENT; SMOKING; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; VERY HIGH RISK STABLE CORONARY PATIENT;

AGED; CHOLESTEROL, LDL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 79958762986     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.591379     Document Type: Article

References (38)

1. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-82
2. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1-10
3. Vulic D, Loncar S, Krneta M, et al. Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005 - 2006. Arch Med Sci 2010;6:270-5
4. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
5. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 (Pubitemid 40471450)
6. Cholesterol Treatment Trialists (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
7. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine Search Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658-69
8. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39 (Pubitemid 38924592)
9. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96:556-63 (Pubitemid 41132774)
10. Elisaf MS, Nikas N. Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs - the CEPHEUS-Greece survey. Angiology 2010;61:465-74
11. Yan AT, Yan RT, Tan M, et al. Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006;119:676-83
12. Mark L, Paragh G, Karadi I, et al. Changes in attainment of lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary during 2004 - 2008. Arch Med Sci 2010;6:695-700
13. Kim BK, Kim DW, Oh S, et al. Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dl on clinical outcomes in very high-risk patients treated with drug-eluting stents. Coron Artery Dis 2010;21:182-8
14. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
15. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2003;27:S15-35
16. Grundy SM, Brewer HB Jr, Cleeman JI, et al. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8 (Pubitemid 38133916)
17. Panagiotakos DB, Pitsavos C, Stefanadis C. Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr Metab Cardiovasc Dis 2006;16:559-68 (Pubitemid 44780080)
18. Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70
19. Shafer AB. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol 2006;62:123-46
20. Fountoulakis KN, Lacovides A, Samolis S, et al. Reliability, validity and psychometric properties of the Greek translation of the Zung Depression Rating Scale. BMC Psychiatry 2001;1:6
21. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381-95 (Pubitemid 36936159)
22. Papathanasiou G, Georgoudis G, Papandreou M, et al. Reliability measures of the short International Physical Activity Questionnaire (IPAQ) in Greek young adults. Hellenic J Cardiol 2009;50:283-94
23. Rallidis LS, Zolindaki MG, Chatziioakimidis VK, et al. High prevalence and suboptimal treatment of risk factors in Greek coronary patients. Acta Cardiol 2001;56:7-15 (Pubitemid 32267019)
24. Selmer R, Sakshaug S, Skurtveit S, et al. Statin treatment in a cohort of 20212 men and women in Norway according to cardiovascular risk factors and level of education. Br J Clin Pharmacol 2009;67:355-62
25. Mayer O Jr, Simon J, Heidrich J, et al. EUROASPIRE II Study Group. Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy. J Epidemiol Community Health 2004;58:47-52 (Pubitemid 38058032)
26. Kupersmith J. Quality of care in teaching hospitals: a literature review. Acad Med 2005;80:458-66 (Pubitemid 40586471)
27. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 2005;165:2508-13 (Pubitemid 41720013)
28. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008;31:2398-403
29. Ho KT, Chin KW, Ng KS, et al. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs 2006;6:383-91
30. Kim HS, Wu Y, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin 2008;24:1951-63
31. Hermans MP, Castro Cabezas M, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010;26:445-54
32. Dallongevillle J, De Bacquer D, Heidrich J, et al. EUROASPIRE Study Group. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart 2010;96:1744-9
33. Rallidis LS, Hamodraka ES, Foulidis VO, et al. Persistent smokers after myocardial infarction: a group that requires special attention. Int J Cardiol 2005;100:241-5
34. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989;298:784-8 (Pubitemid 19084522)
35. Chelland Campbell S, Moffatt RJ, Stamford BA. Smoking and smoking cessation - the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 2008;201:225-35
36. Katsiki N, Mikhailidis DP, Athyros VG, et al. Are we getting to lipid targets in real life? Arch Med Sci 2010;6:639-41
37. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97(suppl):69C-76C
38. Rallidis LS, Lekakis J, Kremastinos DT. Current questions regarding the use of statins in patients with coronary heart disease. Int J Cardiol 2007;122:188-94. (Pubitemid 350001171)